It’s been a good week for Scancell’s shareholders, as investors seized on early data from the biotech's phase 2 cancer vaccine trial to send its stock up 20%. Preliminary data from the first stage of the study showed that the DNA vaccine, dubbed SCIB1, produced an 82% response rate across 11 patients with advanced melanoma when given in combination with checkpoint inhibitors. This exceeded the 70% milestone for objective response rate (ORR) set by the Oxford, U.K.-based company for the trial, according to a release. Source: Fierce Biotech 19/9/2023